THEMIS MEDICARE LTD.

312.45 -16.62 (-5.32%) Sell

THEMISMED investors hurt by serious losses

13 min read

THEMIS MEDICARE LTD. significantly underperformed today. It fell by -5.32% to close at 312.45. It's recent 5 day performance has been -0.02%, -1.33%, +3.08%, +0.68% and -0.25%.

[Themes containing THEMISMED]

THEMISMED is currently in a bearish trend. Over the last three months trading short signals has not been a profitable strategy for THEMISMED's investors in general. However, this strategy had significantly lower risk when compared to Buy-and-Hold investing (which returned +2.38%). It is therefore better to tread with caution in the current downtrend by limiting your allocation to THEMISMED.

Trend

THEMISMED has been underperforming the NIFTY-50 index in recent time. It showed significant underperformance (compared to the NIFTY-50 index) from 30 Oct, 2016 to 21 Aug, 2018. Over the last 2 years 11 months and 9 days, THEMISMED underperformed the NIFTY-50 index on 56% days.

During the last three months THEMISMED delivered losses on 62% days. However, it still managed to end this period in a profit. It's best return during this period (of +18.21%) was on Friday, 9 Nov, 2018. While it's worst loss in the same period (of -6.17%) was on Thursday, 15 Nov, 2018. The longest stort-term trend during this period was 5 losing days, which started on 27 Dec, 2018 and ended on 2 Jan, 2019. This bearish trend lost -6.39% of investor capital.

During the last year THEMISMED had 3 profitable months and 9 loss making months. THEMISMED returned profits in fewer months than NIFTY-50 index. THEMISMED significantly outperformed NIFTY-50 index in Nov 2018, when it returned +20.94% compared to +6.56% returned by NIFTY-50 index during it's best month in the last one year - Jul 2018. THEMISMED had a longer winning streak of losing months than NIFTY-50 index. It went down in 6 straight months (from Feb 2018 to Jul 2018) during which period it delivered -49.74%.

Finance, like time, devours its own children.
-- Honore de Balzac

THEMISMED is currently seeing overall fall in volatility. In comparison, the NIFTY-50 index is seeing decrease in volatility. During the last three months, there was a significant fall in THEMISMED's volatility from 19 Oct, 2018 to 17 Jan, 2019. While there was a significant fall in the NIFTY-50 index's volatility from 31 Oct, 2018 to 5 Dec, 2018.

Advanced/professional short-term investors should note that THEMISMED has significant negative skewness in it's return distribution. This indicates that THEMISMED is very risky for short-term investment and can significantly underperform for long durations.

NIFTY-50 index has more chance of extreme outcomes than THEMISMED. Therefore, NIFTY-50 must receive a lower allocation than THEMISMED in your portfolio. NIFTY-50 index usually has shorter drawdown period than THEMISMED.

Based on your interest in THEMISMED you may find it interesting to know that RESPONIND has shown remarkable performance this year and deserves to be on every investors' watchlist.

Want to improve your Portfolio's performance?

Spotalpha's Portfolio optimizer is all you need to improve your returns and reduce your risk.
Optimize Portfolio NOW
If you liked what you read here ...

... we have a small favour to ask. Help us bring the power of algorithmic trading strategies to individual investors.

All content in this article was automatically generated by algorithms. This ensures that there are no human biases in the analysis provided. This approach to investing is not new and has been around for more than three decades. Yet, it has been available to only the most affluent or elite investors leaving individual investors to trade on emotions (such as fear and greed), intuition and poor analysis from third-parties. We want to change this.

We want to empower investors with all the tools and analysis required by them to make a rational investment decision.

If you found Spotalpha useful, consider making a contribution. For as little as $5 you can support our efforts and it takes less than a minute. Thank you. Contribute
Share with friends   WhatsApp   Facebook   Twitter